Literature DB >> 18505426

Reduction of forkhead box P3 levels in CD4+CD25high T cells in patients with new-onset systemic lupus erythematosus.

B Zhang1, X Zhang, F Tang, L Zhu, Y Liu.   

Abstract

The aim of this study was to quantify and evaluate the forkhead box P3 (FoxP3) expression regulatory T cells in new-onset systemic lupus erythematosus (SLE) patients before and after treatment. Forty-four newly diagnosed and untreated SLE patients, including 24 with active disease (SLEDAI > or = 10) and 20 with inactive disease (SLEDAI < 5), were enrolled in this study. Twenty-one age- and sex-matched healthy volunteers were also included as controls. Peripheral blood samples were collected and mononuclear cells isolated. The expression of CD25 and FoxP3 in CD4(+) T cells were analysed with flow cytometry. CD4(+)CD25(+) (3.95-13.04%) and CD4(+)CD25(high) (0.04-1.34%) T cells in peripheral blood in untreated patients with new-onset active lupus were significantly lower than that in the patients with inactive lupus (7.27-24.48%, P < 0.05 and 0.14-3.07% P < 0.01 respectively) and that in healthy controls (5.84-14.84%, P < 0.05). Interestingly, the decrease in CD4(+)CD25(high) T cells was restored significantly in patients with active lupus after corticosteroid treatment. There was, however, a significantly higher percentage of CD4(+)FoxP3(+) T cells in patients with active (5.30-23.00%) and inactive (7.46-17.38%) new-onset lupus patients compared with healthy control subjects (2.51-12.94%) (P < 0.01). Intriguingly, CD25 expression in CD4(+)FoxP3(+) T cells in patients with active lupus (25.24-62.47%) was significantly lower than that in those patients with inactive lupus (30.35-75.25%, P < 0.05) and healthy controls (54.83-86.38%, P < 0.01). Most strikingly, the levels of FoxP3 expression determined by mean fluorescence intensity in CD4(+)CD25(high) cells in patients with active SLE were significantly down-regulated compared with healthy subjects (130 +/- 22 versus 162 +/- 21, P = 0.012). CD4(+)CD25(high) T cells are low in new-onset patients with active SLE and restored after treatment. Despite that the percentage of CD4(+)FoxP3(+) T cells appear high, the levels of FoxP3 expression in CD4(+)CD25(high) T cells are down-regulated in untreated lupus patients. There is a disproportional expression between CD25(high) and FoxP3(+) in new-onset patients with active SLE.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505426      PMCID: PMC2492897          DOI: 10.1111/j.1365-2249.2008.03686.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  25 in total

1.  Induction of antigen-specific immunologic tolerance by in vivo and in vitro antigen-specific expansion of naturally arising Foxp3+CD25+CD4+ regulatory T cells.

Authors:  Eiji Nishimura; Toshiko Sakihama; Ruka Setoguchi; Koichi Tanaka; Shimon Sakaguchi
Journal:  Int Immunol       Date:  2004-07-05       Impact factor: 4.823

2.  CD4+CD25+ T cells prevent the development of organ-specific autoimmune disease by inhibiting the differentiation of autoreactive effector T cells.

Authors:  Richard J DiPaolo; Deborah D Glass; Karen E Bijwaard; Ethan M Shevach
Journal:  J Immunol       Date:  2005-12-01       Impact factor: 5.422

3.  Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood.

Authors:  C A Lawson; A K Brown; V Bejarano; S H Douglas; C H Burgoyne; A S Greenstein; A W Boylston; P Emery; F Ponchel; J D Isaacs
Journal:  Rheumatology (Oxford)       Date:  2006-03-29       Impact factor: 7.580

4.  Regulatory T cells in patients with systemic lupus erythematosus.

Authors:  Brenda Alvarado-Sánchez; Berenice Hernández-Castro; Diana Portales-Pérez; Lourdes Baranda; Esther Layseca-Espinosa; Carlos Abud-Mendoza; Ana C Cubillas-Tejeda; Roberto González-Amaro
Journal:  J Autoimmun       Date:  2006-08-04       Impact factor: 7.094

5.  Proinflammatory cytokines (TNF-alpha and IL-6) in Egyptian patients with SLE: its correlation with disease activity.

Authors:  Alaa Sabry; Hussein Sheashaa; Amr El-Husseini; Khaleed Mahmoud; Khaleed F Eldahshan; Shahir K George; Ehab Abdel-Khalek; E M El-Shafey; Hamdy Abo-Zenah
Journal:  Cytokine       Date:  2006-10-05       Impact factor: 3.861

6.  Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis.

Authors:  Holm H Uhlig; Janine Coombes; Christian Mottet; Ana Izcue; Claire Thompson; Andrea Fanger; Andrea Tannapfel; Jason D Fontenot; Fred Ramsdell; Fiona Powrie
Journal:  J Immunol       Date:  2006-11-01       Impact factor: 5.422

7.  Global natural regulatory T cell depletion in active systemic lupus erythematosus.

Authors:  Makoto Miyara; Zahir Amoura; Christophe Parizot; Cécile Badoual; Karim Dorgham; Salim Trad; Dominique Nochy; Patrice Debré; Jean-Charles Piette; Guy Gorochov
Journal:  J Immunol       Date:  2005-12-15       Impact factor: 5.422

8.  Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids.

Authors:  A Suárez; P López; J Gómez; C Gutiérrez
Journal:  Ann Rheum Dis       Date:  2006-04-10       Impact factor: 19.103

9.  Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes.

Authors:  Todd M Brusko; Clive H Wasserfall; Michael J Clare-Salzler; Desmond A Schatz; Mark A Atkinson
Journal:  Diabetes       Date:  2005-05       Impact factor: 9.461

10.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11
View more
  26 in total

1.  Involvement of T helper type 17 and regulatory T cell activity in tumour immunology of bladder carcinoma.

Authors:  L J Chi; H T Lu; G L Li; X M Wang; Y Su; W H Xu; B Z Shen
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 2.  Natural regulatory T cells in autoimmunity.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Autoimmunity       Date:  2010-11-23       Impact factor: 2.815

Review 3.  Regulatory T cells in autoimmune disease.

Authors:  Margarita Dominguez-Villar; David A Hafler
Journal:  Nat Immunol       Date:  2018-06-20       Impact factor: 25.606

4.  Quantification of regulatory T cells in peripheral blood of patients with systemic lupus erythematosus.

Authors:  Mojtaba Habibagahi; Zahra Habibagahi; Mansooreh Jaberipour; Amir Aghdashi
Journal:  Rheumatol Int       Date:  2010-04-02       Impact factor: 2.631

5.  B cell-derived IL-10 suppresses inflammatory disease in Lyn-deficient mice.

Authors:  Patrizia Scapini; Chrystelle Lamagna; Yongmei Hu; Karim Lee; Qizhi Tang; Anthony L DeFranco; Clifford A Lowell
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-12       Impact factor: 11.205

Review 6.  SLE and pregnancy: the potential role for regulatory T cells.

Authors:  Clare Tower; Ian Crocker; Debora Chirico; Philip Baker; Ian Bruce
Journal:  Nat Rev Rheumatol       Date:  2010-08-24       Impact factor: 20.543

7.  Lupus-Prone Mice Resist Immune Regulation and Transplant Tolerance Induction.

Authors:  B T Stocks; A J Wilhelm; C S Wilson; A F Marshall; N E Putnam; A S Major; D J Moore
Journal:  Am J Transplant       Date:  2015-09-15       Impact factor: 8.086

8.  Down-regulation of A20 mRNA expression in peripheral blood mononuclear cells from patients with systemic lupus erythematosus.

Authors:  Di Li; Lei Wang; Yuchen Fan; Lijun Song; Chun Guo; Faliang Zhu; Lining Zhang; Yongyu Shi
Journal:  J Clin Immunol       Date:  2012-08-17       Impact factor: 8.317

Review 9.  CD4+FOXP3+ T regulatory cells in human autoimmunity: more than a numbers game.

Authors:  S Alice Long; Jane H Buckner
Journal:  J Immunol       Date:  2011-09-01       Impact factor: 5.422

10.  Subpopulations of regulatory T cells in rheumatoid arthritis, systemic lupus erythematosus, and Behcet's disease.

Authors:  Jae-Ryong Kim; Jin-Nyeong Chae; Sang-Hyon Kim; Jung-Sook Ha
Journal:  J Korean Med Sci       Date:  2012-08-22       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.